180 related articles for article (PubMed ID: 21255685)
21. [Recommendations for prevention of community-acquired pneumonia with bacteremia as the leading form of invasive pneumococcal infections in the population of people over 50 years of age and risk groups above 19 years of age].
Albrecht P; Antczak A; Hryniewicz W; Skoczyńska A; Radzikowski A; Kedziora-Kornatowska K; Bernatowska E; Stompór T; Grodzicki T; Gyrczuk E; Imiela J; Jedrzejczak W; Windak A
Pol Merkur Lekarski; 2014 Feb; 36(212):79-87. PubMed ID: 24720101
[TBL] [Abstract][Full Text] [Related]
22. Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide Vaccine.
Glesby MJ; Watson W; Brinson C; Greenberg RN; Lalezari JP; Skiest D; Sundaraiyer V; Natuk R; Gurtman A; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
J Infect Dis; 2015 Jul; 212(1):18-27. PubMed ID: 25395187
[TBL] [Abstract][Full Text] [Related]
23. Updated recommendations for prevention of invasive pneumococcal disease among adults using the 23-valent pneumococcal polysaccharide vaccine (PPSV23).
;
MMWR Morb Mortal Wkly Rep; 2010 Sep; 59(34):1102-6. PubMed ID: 20814406
[TBL] [Abstract][Full Text] [Related]
24. Revaccination with 23-valent pneumococcal polysaccharide vaccine in the Japanese elderly is well tolerated and elicits immune responses.
Kawakami K; Kishino H; Kanazu S; Toshimizu N; Takahashi K; Sterling T; Wang M; Musey L
Vaccine; 2016 Jul; 34(33):3875-81. PubMed ID: 27265450
[TBL] [Abstract][Full Text] [Related]
25. Immunogenicity and safety of a second administration of 13-valent pneumococcal conjugate vaccine 5 years after initial vaccination in adults 50 years and older.
Frenck RW; Fiquet A; Gurtman A; van Cleeff M; Davis M; Rubino J; Smith W; Sundaraiyer V; Sidhu M; Emini EA; Gruber WC; Scott DA; Schmoele-Thoma B;
Vaccine; 2016 Jun; 34(30):3454-62. PubMed ID: 27155493
[TBL] [Abstract][Full Text] [Related]
26. A prospective study on antibody response to repeated vaccinations with pneumococcal capsular polysaccharide in splenectomized individuals with special reference to Hodgkin's lymphoma.
Landgren O; Björkholm M; Konradsen HB; Söderqvist M; Nilsson B; Gustavsson A; Axdorph U; Kalin M; Grimfors G
J Intern Med; 2004 Jun; 255(6):664-73. PubMed ID: 15147530
[TBL] [Abstract][Full Text] [Related]
27. Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine.
Gadzinowski J; Albrecht P; Hasiec B; Konior R; Dziduch J; Witor A; Mellelieu T; Tansey SP; Jones T; Sarkozy D; Emini EA; Gruber WC; Scott DA
Vaccine; 2011 Apr; 29(16):2947-55. PubMed ID: 21335032
[TBL] [Abstract][Full Text] [Related]
28. A randomized study comparing combined pneumococcal conjugate and polysaccharide vaccination schedules in adults.
Lazarus R; Clutterbuck E; Yu LM; Bowman J; Bateman EA; Diggle L; Angus B; Peto TE; Beverley PC; Mant D; Pollard AJ
Clin Infect Dis; 2011 Mar; 52(6):736-42. PubMed ID: 21367726
[TBL] [Abstract][Full Text] [Related]
29. Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide-protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
Jackson LA; Neuzil KM; Nahm MH; Whitney CG; Yu O; Nelson JC; Starkovich PT; Dunstan M; Carste B; Shay DK; Baggs J; Carlone GM
Vaccine; 2007 May; 25(20):4029-37. PubMed ID: 17391816
[TBL] [Abstract][Full Text] [Related]
30. IgG antibody concentrations after immunization with 11-valent mixed-carrier pneumococcal conjugate vaccine in efficacy trial against pneumonia among Filipino infants.
Soininen A; Nohynek H; Lucero M; Jousimies K; Ugpo J; Williams G; Käyhty H;
Vaccine; 2009 May; 27(20):2680-8. PubMed ID: 19428879
[TBL] [Abstract][Full Text] [Related]
31. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-infected pregnant women and kinetics of passively acquired antibodies in young infants.
Almeida Vde C; Mussi-Pinhata MM; De Souza CB; Kubo CA; Martinez EZ; Carneiro-Sampaio MM; Duarte G
Vaccine; 2009 Jun; 27(29):3856-61. PubMed ID: 19443091
[TBL] [Abstract][Full Text] [Related]
32. Circulating pneumococcal specific plasma and memory B cells in the elderly two years after pneumococcal conjugate versus polysaccharide vaccination.
Baxendale HE; Johnson M; Keating SM; Ashton L; Burbidge P; Woodgate S; Southern J; Miller E; Goldblatt D
Vaccine; 2010 Oct; 28(42):6915-22. PubMed ID: 20708698
[TBL] [Abstract][Full Text] [Related]
33. Antibody persistence ten years after first and second doses of 23-valent pneumococcal polysaccharide vaccine, and immunogenicity and safety of second and third doses in older adults.
Musher DM; Manoff SB; McFetridge RD; Liss CL; Marchese RD; Raab J; Rueda AM; Walker ML; Hoover PA
Hum Vaccin; 2011 Sep; 7(9):919-28. PubMed ID: 21860256
[TBL] [Abstract][Full Text] [Related]
34. Safety, immunogenicity and kinetics of immune response to 7-valent pneumococcal conjugate vaccine in children with idiopathic nephrotic syndrome.
Liakou CD; Askiti V; Mitsioni A; Stefanidis CJ; Theodoridou MC; Spoulou VI
Vaccine; 2011 Sep; 29(40):6834-7. PubMed ID: 21803106
[TBL] [Abstract][Full Text] [Related]
35. Immunogenicity of a heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska native, and non-native American children aged <2 years.
Miernyk KM; Parkinson AJ; Rudolph KM; Petersen KM; Bulkow LR; Greenberg DP; Ward JI; Brenneman G; Reid R; Santosham M
Clin Infect Dis; 2000 Jul; 31(1):34-41. PubMed ID: 10913393
[TBL] [Abstract][Full Text] [Related]
36. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases.
Cherif H; Landgren O; Konradsen HB; Kalin M; Björkholm M
Vaccine; 2006 Jan; 24(1):75-81. PubMed ID: 16107293
[TBL] [Abstract][Full Text] [Related]
37. The effect of 23-valent pneumococcal polysaccharide vaccine on immunological priming induced by 7-valent conjugate vaccine in asplenic subjects with beta-thalassemia.
Orthopoulos GV; Theodoridou MC; Ladis VA; Tsousis DK; Spoulou VI
Vaccine; 2009 Jan; 27(3):350-4. PubMed ID: 19010369
[TBL] [Abstract][Full Text] [Related]
38. Comparison of an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal polysaccharide and pneumococcal conjugate vaccines in children and young adults with sickle cell disease.
Vernacchio L; Romero-Steiner S; Martinez JE; MacDonald K; Barnard S; Pilishvili T; Carlone GM; Ambrosino DM; Molrine DC
J Infect Dis; 2000 Mar; 181(3):1162-6. PubMed ID: 10720547
[TBL] [Abstract][Full Text] [Related]
39. Immunogenicity and safety of a pneumococcal conjugate 7-valent vaccine in infants with sickle cell disease.
Reinert P; Benkerrou M; de Montalembert M; Lesprit E; Abadie I; Bernaudin F; Doit C; Bingen E; Tetelboum R; Bonnet E
Pediatr Infect Dis J; 2007 Dec; 26(12):1105-9. PubMed ID: 18043446
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of sequential pneumococcal vaccination in subjects splenectomised for hereditary spherocytosis.
Stoehr GA; Rose MA; Eber SW; Heidemann K; Schubert R; Zielen S
Br J Haematol; 2006 Mar; 132(6):788-90. PubMed ID: 16487181
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
